| Followers | 22 |
| Posts | 1630 |
| Boards Moderated | 1 |
| Alias Born | 09/25/2018 |
Sunday, October 16, 2022 4:35:00 PM
Did nwbo release TLD - yes. Doesn't matter who presented it. Company acknowledged it in a PR.
Quiet period - No. Fabricated by apologists as a catch-all excuse for poor nwbo communication.
ASCO - nothing new
Liau was genuinely ill. European covid quarantine restrictions were so strict at the time that it would have been impractical for her to present even if she felt up to it.
I believe .gov endpoints were changed during the week after 5/10. To me, changing to OS as primary is fine as it's a more relevant endpoint than PFS.
If external controls were specified at the start of the trial, that would be fine, but not as a post hoc change. Also note that predictive characteristics are all skewed in nwbo's favor as shown on page 19 of the NYAS presentation.
Recurrent GBM wasn't even part of the original endpoints. Those new endpoints are a post hoc Hail Mary attempt to salvage something from the trial.
Quiet period - No. Fabricated by apologists as a catch-all excuse for poor nwbo communication.
ASCO - nothing new
Liau was genuinely ill. European covid quarantine restrictions were so strict at the time that it would have been impractical for her to present even if she felt up to it.
I believe .gov endpoints were changed during the week after 5/10. To me, changing to OS as primary is fine as it's a more relevant endpoint than PFS.
If external controls were specified at the start of the trial, that would be fine, but not as a post hoc change. Also note that predictive characteristics are all skewed in nwbo's favor as shown on page 19 of the NYAS presentation.
Recurrent GBM wasn't even part of the original endpoints. Those new endpoints are a post hoc Hail Mary attempt to salvage something from the trial.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
